Welcome to BioPro Connect

Our newsletter focused on the bioprocessing of biologics-based therapeutics and vaccines. In each issue, we’ll provide you with the latest news and topics of interest focused on optimizing your process and mitigating risk.

7 things to know about biosimilars

Productivity—doing more with less

The industry continues to drive to find process efficiencies and reduce costs. Here are some of our innovations that are helping our customers maximize their resources.

A day in the life: focused on risk mitigation


Meet Janelle Halesworth, our business continuity management systems manager. “We are dedicated to developing, maintaining, and continually improving our business continuity management system in order to ensure personnel safety, a continuous supply chain for customers, and reduced risk and loss from business interruption events.”


Featured video: Novel methods for glycan analysis

Learn about the first glycan analysis method to combine both high throughput and high quality. View video ›

Join the conversation

Check out our weekly blog for the latest news and trends in the industry.

See the blog ›

By the numbers: 14

Not-approved complete response letters issued by FDA in 2016, compared to 2 in 2015. The most common reason cited was non-compliance with cGMP regulations.*

* Mullard, Asher “2016 FDA drug approvals.” Nature Reviews Drug Discovery. February 2017. Pages 73–76.

Upcoming events

We look forward to connecting with you at an upcoming event to understand how we might partner together to optimize your process from reducing risk to increasing efficiency. A list of our upcoming events is included below or

View our full event calendar ›                                                                        Top

July 16-19PREPPhiladelphia, PA
Aug 22-24P-mecSeoul, Korea
Sep. 12–13Bioanalytical/Analytical SummitPrague, CZ
Sep. 17–20CE PharmBoston, MA
Sep. 25–28BPI BostonBoston, MA

Tell us what you think

We’d love to hear from you about suggestions and topics that you’d like to see featured in our newsletter or our weekly blog.  We’re listening – send your feedback.

For Research Use or Further Manufacturing. Not for diagnostic use or direct administration into humans or animals.